Baseline descriptive characteristics of participants
| Overall cohort n=56 | Mild reaction n=40 | Anaphylaxis n=16 | |
| Age (years) | 12.7 (8–16.9) | 12.4 (8–16.9) | 13.3 (8.5–15.6) |
| Gender (% male) | 55 | 52 | 62 |
| Age at diagnosis (years) | 2.5 (1–14) | 2.5 (1–12) | 2 .5 (1–14) |
| Previous anaphylaxis to peanut, n (%) | 23 (41) | 11 (27) | 12 (75) |
| Concomitant atopic disease, n (%): | |||
| Allergy to tree nuts | 10 (18) | 9 (22) | 1 (6) |
| Asthma | 39 (70) | 26 (65) | 13 (81) |
| Allergic rhinitis | 44 (79) | 33 (82) | 11 (69) |
| Eczema | 30 (54) | 22 (55) | 8 (50) |
| Skin prick test to peanut (mm) | 9 (3–22) | 9 (3–22) | 8 (4–17) |
| Serum IgE (kUA/L) to: | |||
| Peanut | 60.8 (0.6 to >100) | 51.4 (1.0 to >100) | 77.2 (0.6 to >100) |
| Ara h 1 | 6.8 (>0.1 to <100) | 4.1 (<0.1 to <100) | 31.5 (>0.1 to <100) |
| Ara h 2 | 26.2 (0.2 to >100) | 26.2 (0.6 to <100) | 38.5 (0.21 to <100) |
| Ara h 3 | 0.6 (>0.1 to <100) | 0.4 (>0.1 to 79.3) | 2.57(>0.1 to <100) |
| Eliciting dose at challenge (mg peanut protein) | 143 (3–4443) | 43 (3–1443) | 143 (13–4443) |
Data expressed as median (range) where appropriate.